Related Experiment Videos
Polyvalent group B streptococcal immune globulin for intravenous administration: overview
G W Fischer1, V G Hemming, H P Gloser
1Department of Pediatrics, Uniformed Services University of the Health Sciences, Bethesda, Maryland 20814-4799.
Reviews of Infectious Diseases
|May 1, 1990
Summary
High-titered group B Streptococcus intravenous immunoglobulin (GBS-IVIG) offers superior protection against GBS infections compared to standard IVIG. This pathogen-specific immunoglobulin therapy shows promise for preventing and treating serious bacterial infections, especially in neonates.
Area of Science:
- Immunology
- Microbiology
- Therapeutics
Background:
- Intravenous immunoglobulin (IVIG) therapy is crucial for preventing and treating infections.
- Standard IVIG derived from pooled plasma may have variable antibody titers against specific pathogens.
- Group B Streptococcus (GBS) poses a significant threat, particularly to neonates.
Purpose of the Study:
- To develop and evaluate a high-titered GBS-specific IVIG preparation.
- To compare the efficacy of GBS-IVIG against standard IVIG in vitro and in vivo.
- To assess the potential of pathogen-specific IVIG for infectious disease treatment.
Main Methods:
- Plasma was collected from volunteers immunized with a polyvalent GBS vaccine.
- Processed plasma was used to create high-titered GBS-IVIG.
- In vitro and in vivo studies were conducted to assess GBS-IVIG efficacy against various GBS strains.
Main Results:
- GBS-IVIG demonstrated superior efficacy compared to standard IVIG.
- GBS-IVIG provided protection even with delayed therapy (up to 24 hours post-infection).
- GBS-IVIG enhanced survival across all tested GBS strains, including those resistant to standard IVIG, and at higher challenge doses.
Conclusions:
- High-titered, pathogen-specific IVIG, such as GBS-IVIG, is more effective than standard IVIG.
- Immunizing volunteers is an effective strategy for producing high-titered, pathogen-specific immunoglobulin preparations.
- This approach holds promise for developing targeted therapies against significant bacterial pathogens like GBS.